Research programme: pain and arthritis therapies - Sagene Pharmaceuticals

Drug Profile

Research programme: pain and arthritis therapies - Sagene Pharmaceuticals

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sagene Pharmaceuticals
  • Class Analgesics; Anti-inflammatories; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Arthritis; Pain

Most Recent Events

  • 28 Feb 2018 Preclinical development is ongoing in pain and arthritis in USA (Sagene Pharmaceuticals pipeline, February 2018)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Arthritis in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top